Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
J Infect Dis ; 223(10): 1666-1670, 2021 05 28.
Article in English | MEDLINE | ID: covidwho-1246717

ABSTRACT

A SARS-CoV-2 variant B1.1.7 containing mutation Δ69/70 has spread rapidly in the United Kingdom and shows an identifiable profile in ThermoFisher TaqPath RT-qPCR, S gene target failure (SGTF). We analyzed recent test data for trends and significance. Linked cycle threshold (Ct) values for respiratory samples showed that a low Ct for ORF1ab and N were clearly associated with SGTF. Significantly more SGTF samples had higher inferred viral loads between 1×107 and 1×108. Our conclusion is that patients whose samples exhibit the SGTF profile are more likely to have high viral loads, which may explain higher infectivity and rapidity of spread.


Subject(s)
COVID-19/virology , Polymerase Chain Reaction/methods , SARS-CoV-2/physiology , Viral Load , COVID-19/epidemiology , Humans , Linear Models , Polymerase Chain Reaction/standards , SARS-CoV-2/classification , SARS-CoV-2/genetics , Taq Polymerase
2.
PLoS Biol ; 19(4): e3001216, 2021 04.
Article in English | MEDLINE | ID: covidwho-1207620

ABSTRACT

Lateral flow devices (LFDs) are quickly being implemented for use in large-scale population surveillance programs for SARS-CoV-2 infection in the United Kingdom. These programs have been piloted in city-wide screening in the city of Liverpool and are now being rolled out to support care home visits and the return home of University students for the Christmas break. Here, we present data on the performance of LFDs to test almost 8,000 students at the University of Birmingham between December 2 and December 9, 2020. The performance is validated against almost 800 samples using PCR performed in the University Pillar 2 testing lab and theoretically validated on thousands of Pillar 2 PCR testing results performed on low-prevalence care home testing samples. Our data show that LFDs do not detect infections presenting with PCR Ct values over 29 to 30 as determined using the Thermo Fisher TaqPath asssay. This may be of particular importance in detecting individuals that are either at the early, or late stages of infection, and reinforces the need for frequent, recurrent testing.


Subject(s)
COVID-19 Serological Testing , COVID-19/diagnosis , Carrier State/diagnosis , SARS-CoV-2/isolation & purification , COVID-19/epidemiology , COVID-19 Nucleic Acid Testing , Carrier State/epidemiology , Humans , Immunoassay , Mass Screening , Prevalence , SARS-CoV-2/genetics , SARS-CoV-2/immunology , Sensitivity and Specificity , United Kingdom/epidemiology , Universities
SELECTION OF CITATIONS
SEARCH DETAIL